Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients
作者： A.M. Riccio , R.W. Dal Negro , C. Micheletto , L. De Ferrari , C. Folli
DOI: 10.1177/039463201202500217
关键词:
摘要: Severe persistent asthma causes a substantial morbidity and mortality burden is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic omalizumab: recombinant humanised murine against IgE antibodies. aim of the present study to investigate effect long-term anti-IgE on thickening reticular basement membrane (RBM) eosinophil infiltration in bronchial biopsies from asthma. Biopsies were obtained 11 before after (12 months) treatment omalizumab. RBM thickness eosinophils measured by using light microscope image analysis. A significant mean reduction one-year omalizumab treatment. No correlation between was found. each pre...
sagepub.com
core.ac.uk
sci-hub.se 参考文章(34)
Connie CW Hsia, Dallas M Hyde, Matthias Ochs, Ewald R Weibel, An Official Research Policy Statement of the American Thoracic Society/European Respiratory Society: Standards for Quantitative Assessment of Lung Structure American Journal of Respiratory and Critical Care Medicine. ,vol. 181, pp. 394- 418 ,(2010) , 10.1164/RCCM.200809-1522ST
D. Descalzi, C. Folli, G. Nicolini, A. M. Riccio, C. Gamalero, F. Scordamaglia, G. W. Canonica, Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy. ,vol. 63, pp. 432- 437 ,(2008) , 10.1111/J.1398-9995.2007.01582.X
Robert F. Lemanske, William W. Busse, Asthma: Clinical expression and molecular mechanisms Journal of Allergy and Clinical Immunology. ,vol. 125, pp. S95- S102 ,(2010) , 10.1016/J.JACI.2009.10.047
H Booth, I Richmond, C Ward, P V Gardiner, R Harkawat, E H Walters, Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine. ,vol. 152, pp. 45- 52 ,(1995) , 10.1164/AJRCCM.152.1.7599861
Christina Miranda, Ashley Busacker, Silvana Balzar, John Trudeau, Sally E. Wenzel, Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation The Journal of Allergy and Clinical Immunology. ,vol. 113, pp. 101- 108 ,(2004) , 10.1016/J.JACI.2003.10.041
EDWARD S. SCHULMAN, Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. American Journal of Respiratory and Critical Care Medicine. ,vol. 164, ,(2001) , 10.1164/AJRCCM.164.SUPPLEMENT_1.2103025
Pranabashis Haldar, Christopher E. Brightling, Beverley Hargadon, Sumit Gupta, William Monteiro, Ana Sousa, Richard P. Marshall, Peter Bradding, Ruth H. Green, Andrew J. Wardlaw, Ian D. Pavord, Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma The New England Journal of Medicine. ,vol. 360, pp. 973- 984 ,(2009) , 10.1056/NEJMOA0808991
SALLY E. WENZEL, LAWRENCE B. SCHWARTZ, ESTHER L. LANGMACK, JANET L. HALLIDAY, JOHN B. TRUDEAU, ROBYN L. GIBBS, HONG WEI CHU, Evidence That Severe Asthma Can Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and Clinical Characteristics American Journal of Respiratory and Critical Care Medicine. ,vol. 160, pp. 1001- 1008 ,(1999) , 10.1164/AJRCCM.160.3.9812110
Stephen Holgate, Roland Buhl, Jean Bousquet, Nicola Smith, Zoya Panahloo, Pablo Jimenez, The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respiratory Medicine. ,vol. 103, pp. 1098- 1113 ,(2009) , 10.1016/J.RMED.2009.03.008
J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, S. Wenzel, H. Fox, S. Hedgecock, M. Blogg, G. Della Cioppa, The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy. ,vol. 60, pp. 302- 308 ,(2005) , 10.1111/J.1398-9995.2004.00770.X